Amyloid beta toxicity dependent upon endothelial cell state

Neuroscience Letters

Volumn 441, Issue 3, 2008, Pages 319-322

  Balcells, Mercedes ^a,b   Wallins, Joseph S ^a   Edelman, Elazer R ^a,c  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's; Amyloid beta; Cerebral amyloid angiopathy; Endothelium repair

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; AORTA; ARTICLE; CELL DAMAGE; CELL GROWTH; CELL VIABILITY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CATTLE; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; CYTOPROTECTION; DRUG RESISTANCE; ENDOTHELIAL CELLS; EPITHELIAL CELLS; MYOCYTES, SMOOTH MUSCLE; NERVE DEGENERATION; NEUROTOXINS; PEPTIDE FRAGMENTS; RATS;

EID: 47249165979     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.06.061     Document Type: Article

References (27)

1. Attems J., Lintner F., and Jellinger K.A. Amyloid beta peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. (Berl.) 107 (2004) 283-291
2. Brooks R.A., Burrin J.M., and Kohner E.M. Characterization of release of basic fibroblast growth factor from bovine retinal endothelial cells in monolayer cultures. Biochem. J. 276 Pt 1 (1991) 113-120
3. Campbell J.H., Kocher O., Skalli O., Gabbiani G., and Campbell G.R. Arteriosclerosis 9 (September-October) 5 (1989) 633-643
4. Cantara S., Donnini S., Morbidelli L., Giachetti A., Schulz R., Memo M., and Ziche M. Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. FASEB J. 18 (2004) 1943-1945
5. Cantara S., Ziche M., and Donnini S. Opposite effects of beta amyloid on endothelial cell survival: role of fibroblast growth factor-2 (FGF-2). Pharmacol. Rep. 57 Suppl. (2005) 138-143
6. Chen Y.R., and Glabe C.G. Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J. Biol. Chem. 281 (2006) 24414-24422
7. Donnini S., Cantara S., Morbidelli L., Giachetti A., and Ziche M. FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ 13 (2006) 1088-1096
8. Ferreira S.T., Vieira M.N., and De Felice F.G. Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases. IUBMB Life 59 (2007) 332-345
9. Fezoui Y., Hartley D.M., Harper J.D., Khurana R., Walsh D.M., Condron M.M., Selkoe D.J., Lansbury Jr. P.T., Fink A.L., and Teplow D.B. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid 7 (2000) 166-178
10. Finder V.H., and Glockshuber R. Amyloid-beta aggregation. Neurodegener. Dis. 4 (2007) 13-27
11. Folin M., Baiguera S., Tommasini M., Guidolin D., Conconi M.T., De Carlo E., Nussdorfer G.G., and Parnigotto P.P. Effects of beta-amyloid on rat neuromicrovascular endothelial cells cultured in vitro. Int. J. Mol. Med. 15 (2005) 929-935
12. Gabbiani G. Control of smooth muscle cell activation. Arterioscler. Thromb. Vasc. Biol. 24 (May) 5 (2004) 804-805
13. Glukhova M.A., Kabakov A.E., Frid M.G., Ornatsky O.I., Belkin A.M., Mukhin D.N., Orekhov A.N., Koteliansky V.E., and Smirnov V.N. Modulation of human aorta smooth muscle cell phenotype: a study of muscle-specific variants of vinculin, caldesmon, and actin expression. Proc. Natl. Acad. Sci. U.S.A. 85 (December) 24 (1988) 9542-9546
14. Gordon P.B., Choi H.U., Conn G., Ahmed A., Ehrmann B., Rosenberg L., and Hatcher V.B. Extracellular matrix heparan sulfate proteoglycans modulate the mitogenic capacity of acidic fibroblast growth factor. J. Cell. Physiol. 140 (1989) 584-592
15. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., and Blennow K. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging (May 16, 2008) (Epub)
16. Hartmann T., Bieger S.C., Bruhl B., Tienari P.J., Ida N., Allsop D., Roberts G.W., Masters C.L., Dotti C.G., Unsicker K., and Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat. Med. 3 (1997) 1016-1020
17. Mok S.S., Losic D., Barrow C.J., Turner B.J., Masters C.L., Martin L.L., and Small D.H. The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. J. Neurochem. 96 (2006) 53-64
18. Mok S.S., Sberna G., Heffernan D., Cappai R., Galatis D., Clarris H.J., Sawyer W.H., Beyreuther K., Masters C.L., and Small D.H. Expression and analysis of heparin-binding regions of the amyloid precursor protein of Alzheimer's disease. FEBS Lett. 415 (1997) 303-307
19. Nguyen P.H., Li M.S., Stock G., Straub J.E., and Thirumalai D. Monomer adds to preformed structured oligomers of Abeta-peptides by a two-stage dock-lock mechanism. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 111-116
20. Nugent M.A., Karnovsky M.J., and Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ. Res. 73 (December) 6 (1993) 1051-1060
21. Parameshwaran K., Sims C., Kanju P., Vaithianathan T., Shonesy B.C., Dhanasekaran M., Bahr B.A., and Suppiramaniam V. Amyloid beta-peptide Abeta(1-42) but not Abeta(1-40) attenuates synaptic AMPA receptor function. Synapse 61 (2007) 367-374
22. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B., and Selkoe D.J. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270 (1995) 9564-9570
23. Seabrook G.R., Ray W.J., Shearman M., and Hutton M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol. Interv. 7 (October) 5 (2007) 261-270
24. Soffer D. Cerebral amyloid angiopathy-a disease or age-related condition. Isr. Med. Assoc. J. 8 (2006) 803-806
25. Watson D., Castaño E., Kokjohn T.A., Kuo Y.M., Lyubchenko Y., Pinsky D., Connolly Jr. E.S., Esh C., Luehrs D.C., Stine W.B., Rowse L.M., Emmerling M.R., and Roher A.E. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol. Res. 27 (December) 8 (2005) 869-881
26. Watson D.J., Lander A.D., and Selkoe D.J. Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. J. Biol. Chem. 272 (1997) 31617-31624
27. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M.B., Teplow D.B., Haass C., Seubert P., Koo E.H., and Selkoe D.J. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272 (1997) 7977-7982